Subscribe to news

HSCI’s Licensee, Artgen, Inc., a Maryland, USA Company, Awarded the Maryland Industrial Partnerships (MIPS) Award to Advance Development of its Therapeutic Candidate for Peripheral Arterial Disease

Moscow – 25 July, 2017. PJSC “HSCI” – The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), a leading Russian public biotech company, today announced that its US Licensee, Artgen, Inc., has been selected to receive a collaborative MIPS award with the University of Maryland to advance the development of a gene-therapy drug candidate for the treatment of Peripheral Arterial Disease (PAD).

Artgen, Inc. is a US privately held biotechnology company located in Rockville, MD, whose seed investor and IP licensor is Human Stem Cells Institute. Artgen is developing its lead product as a novel non-viral gene therapy for treatment of vascular diseases, with foundational IP secured from HSCI. The licensed IP is based upon Neovasculgen® which was approved in 2011 for human use in Russia for the treatment of PAD.

Neovasculgen’s mechanism of action - therapeutic angiogenesis - introduces a new approach for the treatment of ischemia: the use of a physiological process of blood vessel creation and growth. Containing the gene of the Vascular Endothelial Growth Factor (VEGF) embedded in a plasmid vector (carrier), Neovasculgen® stimulates the growth of collateral blood vessels and promotes a long-term therapeutic effect and improves patient’s quality of life.

Artgen has received MIPS award in collaboration with the University of Maryland, for the project “Novel targeted imaging applications for PAD” as essential for the development of objective methods for testing the drug candidate effect in patients.

Maryland Industrial Partnerships (MIPS) has been supporting the commercialization of innovative technologies for more than 27 years by combining the efforts of business and university science. MIPS promotes the development and commercialization of products and processes through industry/university research partnerships. MIPS provides matching funds to help Maryland companies pay for the university research. Projects are initiated by the companies to meet their own research and development goals.

HSCI and Artgen are partnering on the project with BioHealth Innovation, Inc. (BHI), Rockville, Maryland.

BioHealth Innovation, Inc. is a regional innovation intermediary that translates market-relevant research into commercial success by connecting management, funding, and markets. BHI supports the transformation of research projects into new business opportunities.

Full Version of the Press Release 

25 July 2017